P&G/Cygnus
This article was originally published in The Tan Sheet
Executive Summary
Announce agreement under which P&G will have exclusive worldwide marketing rights to "at least two" smoking cessation products currently being developed by Cygnus. The deal does not apply to the Nicotrol nicotine patch, which is being marketed in the U.S. and Canada by McNeil Consumer under a recent pact with Cygnus' licensee Kabi Pharmacia ("The Tan Sheet" Jan. 24, p. 13). Cygnus and P&G have a pre-existing agreement to market an OTC using a nontransdermal Cygnus delivery system
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning